Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

IND-Enabling Toxicology Programs for Bispecific T-Cell Engagers (BiTEs) Targeting Hematological Malignancies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

IND-Enabling Toxicology Programs for Bispecific T-Cell Engagers (BiTEs) Targeting Hematological Malignancies

IND-Enabling Toxicology Programs for Bispecific T-Cell Engagers (BiTEs)

CELL & GENE | RNA | BIOLOGICS

Executive Summary

An IND-enabling toxicology program for a Bispecific T-Cell Engager (BiTE) targeting a hematological malignancy must be designed to de-risk two primary liabilities: Cytokine Release Syndrome (CRS) and on-target, off-tumor toxicity. A successful program integrates in vitro cytokine release assays with GxP-compliant in vivo studies in relevant species or humanized models to establish a safe starting dose and characterize the dose-response relationship for both efficacy and toxicity. Franklin Biolabs provides comprehensive toxicology and safety pharmacology programs within our >100,000 sq ft facility, designed to support an 18-24 month IND timeline.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

    What are the primary dose-limiting toxicities (DLTs) for BiTEs?

    The principal DLTs are mechanism-based and include Cytokine Release Syndrome (CRS) and neurotoxicity. These arise from the potent, target-dependent activation of T cells, leading to systemic inflammation and potential neurological events that must be carefully characterized preclinically.

    How is Cytokine Release Syndrome (CRS) evaluated in preclinical models?

    CRS potential is evaluated using a combination of methods. In vitro cytokine release assays using human peripheral blood mononuclear cells (PBMCs) co-cultured with target cells provide initial data. These are followed by in vivo studies, often in humanized models, that include intensive monitoring of systemic cytokines (e.g., IL-6, IFN-γ, TNF-α) and clinical observations.

    What are regulatory expectations for assessing on-target, off-tumor toxicity?

    Regulatory bodies expect a thorough assessment of potential binding and activity on non-malignant tissues that express the target antigen. This is primarily addressed through a comprehensive non-target tissue biodistribution study using immunohistochemistry on a full panel of human tissues, supplemented by extensive histology from pivotal GxP toxicology studies.

    How does the short half-life of many BiTE constructs impact toxicology study design?

    The pharmacokinetic profile directly influences study design. Constructs with a short half-life often necessitate continuous intravenous infusion to maintain therapeutic exposure in vivo. This requires specialized equipment and procedures to ensure animal welfare and the integrity of the toxicology data.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Deconstructing BiTE-Mediated Toxicity

Bispecific T-cell engagers function by physically linking a patient’s T cells to tumor cells, inducing potent, targeted cell lysis. This mechanism, while effective, presents a distinct safety profile. The primary challenge is managing the consequences of profound T cell activation, which can manifest systemically. Understanding the dynamics of T cell activation in different biological compartments is a core component of a predictive safety program.

A robust toxicology program must be designed to answer two questions:

  • What is the dose-response relationship for cytokine release?

  • What is the safety margin relative to on-target, off-tumor effects?

Designing a GxP-Compliant Toxicology Program

The pathway to a successful IND submission for a BiTE is built on a series of well-defined studies. This phased approach allows data from earlier studies to inform the design of subsequent, pivotal GxP investigations. Since our brand launch in 2024, programs developed by our scientific leadership have maintained a 100% IND success rate, a track record extending back to 2019 under previous operational banners.

Study Type Primary Objective Key Endpoints
In Vitro Cytokine Release Quantify dose-dependent cytokine production from human immune cells. IL-2, IL-6, IL-10, TNF-α, IFN-γ levels.
Dose-Range Finding (DRF) Identify a maximum tolerated dose (MTD) or feasible high dose; inform dose selection for pivotal studies. Clinical observations, body weights, limited clinical pathology & histology.
Pivotal GxP Toxicology Characterize the toxicity profile with repeat dosing; identify target organs and establish the NOAEL. Full clinical pathology, coagulation, gross pathology, comprehensive histology.
Safety Pharmacology Evaluate effects on core cardiovascular, respiratory, and central nervous systems. ECG, blood pressure, respiratory rate, functional observational battery (FOB).

Understanding systemic tolerance mechanisms is also a factor. Research into specific organ microenvironments has demonstrated how local cellular interactions can suppress systemic T cell responses (PMID: 19575456). This principle of localized immune modulation is relevant when evaluating potential on-target effects within the liver and interpreting systemic cytokine data for BiTEs, as the liver can be a site for clearance and potential off-tumor activity.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Commitment to Enhanced Animal Welfare

Franklin Biolabs is committed to the highest ethical standards, adhering to all USDA guidelines and the principles of AAALAC International. Our animal welfare strategy is built upon the 3Rs (Reduction, Refinement, and Replacement), ensuring that all studies are scientifically necessary and conducted with the utmost care.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities